BC Innovations | Jun 27, 2019
Product Development

Gene therapy’s next frontier lies beyond rare, monogenic diseases

As in vivo gene therapies continue notching approvals for rare monogenic diseases, the next frontier for the modality will be in treating complex indications without obvious genetic drivers. At least seven companies have clinical or...
BC Innovations | May 15, 2019
Translation in Brief

Lentiviral gene therapy could offer relief to refractory epilepsy patients

Within a year, University College London researchers hope to begin a clinical trial of a gene therapy for epilepsy, a non-monogenic disorder. The hope is that the approach will offer an alternative to brain surgery...
BC Innovations | May 6, 2019
Distillery Therapeutics

KCNA1 gene therapy for epilepsy

DISEASE CATEGORY: Neurology INDICATION: Epilepsy Rat studies suggest KCNA1-based gene therapy could help treat epilepsy. The gene therapy consisted of KCNA1 codon-optimized for expression in human cells and harboring the I400V mutation to increase the...
BC Innovations | Sep 23, 2010
Distillery Techniques

Technology: Markers

Approach Summary Licensing status Publication and contact information Markers Immunohistochemical characterization of medulloblastomas based on dickkopf homolog 1 (DKK1), secreted frizzled-related protein 1 (SFRP1), natriuretic peptide receptor C/guanylate cyclase C (NPR3) and potassium channel Kv1.1...
BC Innovations | Sep 10, 2009
Targets & Mechanisms

Progenitor cell therapy for epilepsy

University of California, San Francisco researchers have developed a cell therapy for epilepsy that aims to reduce the abnormal neuronal excitability that underlies the disease. 1 The transplantation of neuronal precursor cells to specific regions...
Items per page:
1 - 5 of 5